Introduction
============

Prostate cancer (PCa) patients with locally advanced disease are often treated with androgen deprivation therapy (ADT) to prevent tumour progression ([@bib1]). Loss of skeletal muscle mass is a common side effect of ADT ([@bib2], [@bib3], [@bib4]), which in turn might lead to reduced muscular strength and endurance ([@bib5], [@bib6]). Effective interventions to prevent impairments in muscle function during ADT are therefore needed.

Castration is associated with impaired mitochondrial function ([@bib7]). As mitochondrial dysfunction is involved in muscle protein degradation, this might be one of the mechanisms behind ADT-induced loss of muscle mass ([@bib8], [@bib9]). In skeletal muscle, the ubiquitin proteasome system is one of the major sites for protein breakdown, where E3 ligases promote ubiquitin conjugation of proteins destined for breakdown by the 26s proteasome ([@bib10]). Removal of testosterone has been shown to increase the expression of muscle-specific E3 ligases ([@bib11]), and this may also play a role in ADT-induced loss of muscle mass. Strength training, however, has been shown to increase the activity of mitochondrial proteins in elderly men ([@bib12], [@bib13]). Therefore, strength training may be an effective strategy against muscle loss in PCa patients on ADT.

Heat shock proteins (HSPs) are molecular chaperons, essential for proper protein folding of newly synthesized proteins ([@bib14]) and refolding of denatured proteins in order to prevent aggregation ([@bib15]). HSP70, HSP27 and alpha B-crystallin have important roles in reinforcing the cytoskeleton ([@bib16]). Thus, HSPs might prevent denaturation and may even refold denatured proteins before they irreversibly aggregate and are ultimately metabolized via proteolytic pathways ([@bib17]). Consequently, the content of HSPs is increased when muscle cells are exposed to several types of stressors ([@bib18], [@bib19]) and increasing age, at least for the larger HSPs ([@bib20]). This would, in theory, preserve muscle mass, by stabilisation of stressed and damaged proteins ([@bib21]). No studies to date have investigated the effect of strength training on HSPs in PCa patients on ADT.

Although ADT may induce severe side effects on the muscle cellular level, and strength training has the potential to counteract this, no studies to date have addressed this in humans. Therefore, the aim of this exploratory study was to investigate the effect of strength training in PCa patients on ADT, on mitochondrial proteins and indicators of muscle cellular stress. We expected that strength training would increase levels of mitochondrial proteins and decrease levels of HSP and proteins marked for degradation through ubiquitination.

Materials and methods
=====================

This study was conducted as a part of the Physical Exercise and Prostate Cancer (PEPC) trial. All subjects gave their written consent to participate in the study, which conformed to the Declaration of Helsinki. The Regional Committee for Medical and Health Research Ethics, Southeast Region approved the study (protocol nr. 08/212b.2008/4062), and the trial is registered at ClinicalTrials.gov (Nbib658229). Rationale and design of this two-armed randomised controlled trial are published elsewhere ([@bib22]). In short, newly diagnosed PCa patients of intermediate- or high-risk profile on (neo)-adjuvant ADT, 75 years old or younger, were invited. The exclusion criteria were routinely performing strength training, receiving medication for osteoporosis, or suffering from any conditions that could complicate strength training.

Design and randomisation
------------------------

The baseline biopsy was obtained at least 1 month after radiotherapy, corresponding to 5months or more after initiation of ADT depending on the duration of the neo-adjuvant part of ADT. Thereafter, the ADT-treated PCa patients were randomly assigned, in the ratio 1:1, to a strength training group (STG) or a control group (CG) for 16 weeks, when the post-biopsy was obtained.

Strength training program
-------------------------

The strength training program was performed 3 times a week for 16weeks during ongoing ADT. The training sessions progressed from one to three sets throughout the period and included nine exercises: Smith machine half squat, leg press, smith machine standing calf raise, knee flexion, knee extension, chest press, seated row, shoulder press and biceps curl. The first 2weeks were used for light-intensity familiarisation. Thereafter, the training load was 10RM (maximum load that can be repeated 10 times) on Mondays and 6 RM on Fridays. On Wednesdays, a submaximal session was performed with a resistance equivalent to 80--90% of the patient\'s 10 RM load in 10 repetitions. All high-load sessions were performed under supervision. Patients in the CG were encouraged to maintain their current habitual activity level.

Assessments
-----------

All muscle biopsies were obtained the week before and after the intervention. Importantly, to exclude the effect of the last training session in the analysis, all post-intervention biopsies were obtained 72 or 96 h after the last training session in the STG.

Muscle biopsy procedures and homogenisation
-------------------------------------------

The muscle biopsies were collected from the mid part of the vastus lateralis muscle, separated by at least 3 cm to avoid any repeated biopsy effect. After injection of local anaesthetic, Xylocain-epinephrine 10mg/mL+5μg/mL (AstraZeneca, Södertälje, Sweden) and sterilisation of the surface, a 1--2cm incision was made in the skin and the fascia of the vastus lateralis muscle. The biopsies were obtained using a 6-mm Pelomi needle (Albertslund, Denmark; the Bergström technique) and manual suction. Pieces for immunoassays were rinsed in ice cold saline (0.9% NaCl; Braun, Melsungen, Germany) and carefully dissected free of visual fat, connective tissue and blood. Pieces of 50mg were frozen in isopentane on dry ice and stored at −80°C for later homogenisation.

Total protein was extracted from muscle samples using a commercially available kit (T-PER Tissue Protein Extraction Reagent, cat. no. 78510; Thermo Fisher Scientific) according to the manufacturer's procedures. Furthermore, 2% protease and phosphatase inhibitor cocktail (Halt Protease and Phosphatase Inhibitor Cocktail, cat. no. 78440, Thermo Fisher Scientific) and 2% EDTA were added to the lysate dilution according to the manufacturer's procedures.

As the above-described method discards the cytoskeleton fraction of the homogenate, a second muscle sample was fractionated into a cytosol, membrane, cytoskeletal, and nuclear fraction using a commercially available fractionation kit (ProteoExtract Subcellular Proteome Extraction Kit, cat. no. 539790, Calbiochem, EMD Millipore, Darmstadt, Germany) according to the manufacturer's procedures.

Protein concentrations were determined using a commercial kit (BioRad DC Protein micro plate assay, cat. nos 0113, 0114 and 0115, Bio-Rad), a filter photometer (Expert 96, ASYS Hitech, Cambridge, UK) and the provided software (Kim, ver. 5.45.0.1, Daniel Kittrich, Prague, Czech Republic). γ-globulin was used as a standard protein, ranging from 0.125 to 1.5mg/mL. Protein standard curve and samples were analysed in triplicate; standard curve: *r*^2^\>0.9.

Western blot
------------

Equal amount of protein (10--40 μg per well, depending on the fraction loaded) was loaded and separated by precast NuPAGE Novex 4--12% Bis-tris Midi gels (cat. no. NP0321, Invitrogen) for 35--45 min at 200V in cold MES running buffer (NuPAGE MES SDS Running Buffer, cat. no. NP0002, Life Technologies, Invitrogen). All subcellular fractions and time points were routinely loaded on the same gel to enable comparison. Separated proteins were transferred onto immune-blot PVDF membrane (Immuno-blot, cat. no. 162-0177, Bio-Rad) at 30V for 90min in cold transfer buffer (NuPAGE Transfer Buffer, cat. no. NP0006-1, Life Technologies, Invitrogen). Whereas membranes used for HSP70 and alpha B-crystallin ([Table 1](#tbl1){ref-type="table"}) were blocked overnight at 4°C in a 5% fat-free skimmed milk and 0.05% TBS-Tween solution (TBS, cat. no. 170-6435, Bio-Rad; Tween 20, cat. no. 437082Q, VWR International, Radnor, PA, USA; Skim milk, cat. no. 1.15363, Merck). Membranes used for HSP60, cytochrome c oxidase subunit IV (COXIV), citrate synthase, free ubiquitin and total ubiquitinated proteins ([Table 1](#tbl1){ref-type="table"}) were blocked at room temperature (RT) for 2h. Blocked membranes were then incubated with monoclonal primary antibodies for 2 h at RT or overnight at 4°C. Thereafter, membranes were incubated with secondary antibody (goat anti-mouse, cat. no. 31430, Thermo Fisher Scientific/Pierce Biotechnology) diluted 1:30,000 or 1:2000 (anti-rabbit IgG, cat. no. 7074, Cell Signalling) at RT for 1 h. All antibodies were diluted in a 1% fat-free skimmed milk and 0.05% TBS-Tween solution. Between stages, the membranes were washed with 0.05% TBS-Tween. Protein bands were visualised, with horseradish peroxidase (HRP) detection system (Super Signal West Dura Extended Duration Substrate, cat. no. 34076, Thermo Fisher Scientific/Pierce Biotechnology). Chemiluminescence was measured using a CCD image sensor (Kodak Image Station 2000R, Eastman Kodak company, Rochester, NY, USA), and band intensity was calculated using the Carestream Molecular Imaging software (v. 5.0.7.2.2., Carestream Health, New Haven, CT, USA). All samples were analysed in duplicate, and mean values were used for statistical analysis. Representative blots are listed in [Fig. 1](#fig1){ref-type="fig"}, and blots for free ubiquitin and total ubiquitinated proteins in [Fig. 2](#fig2){ref-type="fig"}. Figure 1Representative blots for citrate synthase, COXIV, HSP60, HSP70 and alpha B-crystallin. Figure 2Representative blots for total ubiquitinated proteins and free ubiquitin. Table 1Overview of antibodies used in this study.**Cat. no.LOTHostDilutionManufacturer**HSP70ADI-SPA-81012071118Mouse1:4000Enzo Life Sciences (Farmingdale, NY, USA)Alpha B-crystallineADI-SPA-2229011032Mouse1:4000Enzo Life Sciences (Farmingdale, NY, USA)HSP27ADI-SPA-8009061109Mouse1:10,000Enzo Life Sciences (Farmingdale, NY, USA)HSP27ADI-SPA-8033020917Rabbit1:10,000Enzo Life Sciences (Farmingdale, NY, USA)HSP60SPA-807-E12409Mouse1:4000Stressgen Biotechnologies (Victoria, BC, Canada)COXIVAb14744GR67749-1Mouse1:1000Abcam (UK)Citrate synthaseab96600GR134613-9Rabbit1:12,000Abcam (UK)UbiquitinSPA-203B405440Mouse1:2000Nordic Biosite AB (Täby, Sweden)

Enzyme-linked immunosorbent assay
---------------------------------

Protein quantification of HSP27 was performed using a double-antibody sandwich ELISA developed within our laboratory. Each sub cellular fraction was analysed separately and later combined to give the total cellular amount. A monoclonal capture antibody against HSP27 (25ng per well; mouse anti-HSP27 (Enzo Life Sciences, Farmingdale, NY, USA)) and a polyclonal detection antibody against HSP27 (rabbit anti-HSP27 (Enzo Life Sciences)) was diluted 1:10,000 and HRP conjugate was used as secondary antibody, diluted 1:10,000 (Amersham Biosciences; GE Healthcare Life Sciences, Buckinghamshire, UK). The HSP27 assay was performed in high-binding polystyrene microplates (Costar 3590, Costar, Inc., Corning, NY, USA) using tetramethylbenzidine (TMB Solution, Calbiochem, EMD Biosciences) as substrate, and 1M sulphuric acid as stop solution. Recombinant HSP27 (Enzo Life Sciences) was used as standards (0.0975--25 ng/mL). All samples were diluted 1:300 (cytosolic fraction), 1:100 (membrane fraction) or 1:50 (cytoskeletal fraction) and analysed in triplicate (CV\<10%). The amount of HSP27 was determined using a filter photometer measuring optical density at 450nm.

Statistics
----------

Only patients with both baseline and post-biopsies were included in the analysis. Normality was assessed by visual inspection of plots as well as D'Agostino-Pearson omnibus normality test. Data that passed the normality test were analysed by comparing the mean change between groups by the two-sample *t*-test, and data that failed the normality test (COXIV and total ubiquitinated proteins) were analysed by a nonparametric Wilcoxon matched-pairs signed-rank test. Within-group changes are visualised in graphs by individual relative changes, and within-group mean changes and 95% CIs. Extreme outliers were identified using Bland--Altman plots and removed from the data set. Removal of outliers did not alter any between or within-group changes. Data were analysed using GraphPad Prism 5 (version 5; GraphPad Software, Inc., <http://www.graphpad.com>).

Results
=======

Baseline characteristics
------------------------

Between 2009 and 2011, 104 eligible patients were invited to the PEPC trial and 58 agreed to participate. Of these, 37 patients were willing to undergo muscle biopsies at baseline, of which two patients dropped out due to accidents not related to the study and four refused to undergo post-biopsies due to discomfort. This resulted in 16 patients in the STG and 15 patients in the CG ([Fig. 3](#fig3){ref-type="fig"}). At baseline, the mean duration of ADT (LHRH analogue) was 9 months; other baseline characteristics are listed in [Table 2](#tbl2){ref-type="table"}. Figure 3Consort diagram. Table 2Baseline characteristics.**STG (*n* = 16)CG (*n* = 15)**Age (years) Mean (range)66 (54--76)65 (54--76) [s.d]{.smallcaps}.65Height (m) Mean1.78 (1.70--1.87)1.75 (1.52--1.88) [s.d]{.smallcaps}.0.10.1Weight (kg) Mean90.3 (75.1--114.6)89.8 (70.9--118.3) [s.d]{.smallcaps}.10.814.2Body mass index (kg/m^2^) Mean28.6 (24.1--38.9)29.2 (25.0--35.8) [s.d]{.smallcaps}.3.53.2Risk profile groups Intermediate (proportion of patients)4333 High (proportion of patients)5667Time on ADT at baseline (months) Mean (range)9.2 (7--12)9.3 (6--12) [s.d]{.smallcaps}.1.71.9Total time on ADT (months) Mean (range)18.0 (8--28)20.5 (8--28) [s.d]{.smallcaps}.8.58.3Time from rad. to baseline (months) Mean (range)3.0 (1.2--6.6)2.8 (0.7--5.8) [s.d]{.smallcaps}.1.41.3Testosterone at baseline (mmol/L) Mean (range)0.56 (\<0.40--1.50)0.65 (\<0.40--1.30) [s.d]{.smallcaps}.0.270.26[^1]

Mitochondrial proteins
----------------------

There was no difference in mean change in the levels of citrate synthase (STG: 0.5±19.0%, CG: −5.1±10.3%, *P*=0.35) ([Fig. 4A](#fig4){ref-type="fig"}), COXIV (STG: 85.2±230.4%, CG: 44.1±154.2%, *P*=0.58) ([Fig. 4B](#fig4){ref-type="fig"}) or HSP60 (STG: 9.9±24.0%, CG: 9.8±29.9%, *P*=0.98) ([Fig. 4C](#fig4){ref-type="fig"}) between the groups during the intervention. There was, however, a weak tendency towards a reduction in citrate synthase within the CG (−5.1±10.3%, *P*=0.09) ([Fig. 4A](#fig4){ref-type="fig"}). Figure 4Relative change in citrate synthase (A), COXIV (B) and HSP60 (C). Values are expressed as individual change from baseline to post-assessment. Bars represent group mean and 95% confidence intervals.

Indicators of muscle cellular stress
------------------------------------

There was no difference in mean change between the STG and the CG in HSP70 (STG: −11.2±18.1%, CG: −1.6±23.5%, *P*=0.20) during the intervention period ([Fig. 5A](#fig5){ref-type="fig"}). Also, there was no difference in mean change for the small HSPs: alpha B-crystallin (STG: −9.9±22.6%, CG: −5.0±27.0%, *P*=0.60) ([Fig. 5B](#fig5){ref-type="fig"}) and HSP27 (STG: 66.5± 888.4%, CG: −6.1±843.4%, *P*=0.62) ([Fig. 5C](#fig5){ref-type="fig"}). HSP70 was, however, significantly reduced within the STG (*P*=0.03) ([Fig. 5A](#fig5){ref-type="fig"}). There was no difference in mean change in free ubiquitin (STG: 8.4±49.9%, CG: −13.6±20.2%, *P*=0.16) ([Fig. 6A](#fig6){ref-type="fig"}) or in total ubiquitinated proteins (STG: 34.8 ± 77.6%, CG: 26.0±68.7%, P=0.77) ([Fig. 6B](#fig6){ref-type="fig"}) between the STG and the CG. No within-group changes were observed for any group. Figure 5Relative change in HSP70 (A), alpha B-crystallin (B) and HSP27 (C). Values are expressed as individual change from baseline to post-assessment. Bars represent group mean and 95% confidence intervals. Figure 6Relative change in free ubiquitin (A) and ubiquitinated proteins (B). Values are expressed as individual change from baseline to post-assessment. Bars represent group mean and 95% confidence intervals.

Discussion
==========

This is the first study to evaluate the effect of strength training on mitochondrial proteins and indicators of muscle cellular stress in PCa patients on ADT. Contrary to our expectations, no effect of the intervention was observed in the levels of mitochondrial proteins, HSPs or ubiquitin or ubiquitinated proteins. We did, however, observe decreased levels of HSP70 within the STG from baseline to post-intervention.

The lack of change in mitochondrial proteins in this study is in contrast to studies in elderly men, where strength training has been show to increase the activity of mitochondrial proteins ([@bib12], [@bib13]). Increases have even been reported from strength training in men suffering from mitochondrial myopathies ([@bib23]). As opposed to the above-cited studies, we measured the content of several mitochondrial proteins rather than enzyme activity per se. However, mitochondrial enzymatic activity has been shown to be reliant upon the total amount of enzymes ([@bib24], [@bib25]), and the content of citrate synthase and COXIV is shown to be a reliable marker of mitochondrial content in skeletal muscle ([@bib26], [@bib27]). Interestingly, castration decreases the activity of COXIV, and testosterone supplementation increases the enzymatic activity ([@bib7]). Therefore, the testosterone-suppressed status of the PCa patients in this study may have reduced the mitochondrial adaptation to strength training.

Our Western blot results were normalized to the total amount of protein in each sample. We have previously reported increased muscle fibre area of type II fibres (*P* = 0.03) in the PEPC trial ([@bib28]). Thus, type II fibres are most likely accounting for a larger amount of the total protein content in the post-biopsy compared with the baseline biopsy. This could further explain the lack of increases in mitochondrial proteins in this study, because type I fibres contain a greater mitochondrial mass than type II fibres ([@bib29]). In addition, when both fibre types were combined, there was a tendency towards an increased muscle fibre cross-sectional area (*P*= 0.09) within the STG in the PEPC trial ([@bib28]). Therefore, our results indicate an increase in the absolute mitochondrial mass because our Western blots are normalised to the total protein content, and we report unchanged concentration of mitochondrial proteins.

There were no group differences in mean change in any of the HSPs. However, as expected, we observed reduced levels of HSP70 within the STG. It has been shown that strength training increases the levels of both HSP70 and alpha B-crystallin in young healthy men ([@bib16]), and training-induced HSP response seems to be dependent upon training intensity ([@bib30], [@bib31]). However, all heavy training sessions in the PEPC trial were performed under the supervision of an exercise physiologist to ensure sufficient training intensity. Therefore, we do not suspect that low training intensity could explain the HSP results in this study. However, there are indications in the literature that basal levels of HSPs are elevated in aged muscle compared with younger muscle ([@bib20], [@bib32]). Thus, we suspect that the HSP levels are already elevated at baseline in this study, especially because the PCa patients had been on ADT for 9 months prior to our baseline assessment. Thus, reduced levels of HSPs may indicate a normalisation of the cellular environment.

Moreover, castration has been shown to blunt the normal HSP70 response in cardiac muscle during endurance exercise in rodents ([@bib33]). Interestingly, when the castrated rats were supplemented with DHT, a testosterone metabolite, there was no difference in the HSP70 response compared with intact rats ([@bib33]). Also, some synthetic anabolic steroids have been shown to increase HSP levels in skeletal muscle ([@bib34]). Therefore, androgens seem to play a role in mediating the HSP levels in men, and possibly also the response to exercise. However, the effects of ADT on HSP levels in human skeletal muscle are not known, and we cannot rule out that baseline levels of HSPs in this study were different from healthy subjects.

We did not observe any effect of strength training on the levels of free ubiquitin or ubiquitinated proteins in this study. There are a limited number of studies exploring the levels of ubiquitin in skeletal muscle in the literature; however, elevated levels of ubiquitinated skeletal muscle proteins have been observed after heart failure in rats, and aerobic exercise decreased these levels ([@bib35]). Tendencies towards elevated levels of ubiquitinated muscle proteins were also observed in heart failure patients compared with healthy controls, and aerobic exercise led to non-significant reductions ([@bib35]). To our knowledge, no previous study has investigated the effect of strength training, or testosterone suppression, on the levels ubiquitinated muscle proteins. However, testosterone suppression has been shown to increase the expression of Murf-1 and Atrogin-1 ([@bib11]), which in theory would lead to increased ubiquitination of muscle proteins. Nevertheless, if strength training induces similar effect as described previously for endurance training, testosterone suppression seems to hamper this effect during ADT.

This study suffers from limitations that need to be taken into account, before the results can be generalized. First, our baseline biopsy was obtained 6--12 months after commencing ADT; thus, our results may not represent events occurring immediately after commencing ADT. Second, the sample population available for analysis in this study was of relatively small size, which may have introduced statistical type 2 errors. Therefore, the results of this study must be interpreted with caution. Third, of the 119 patients invited to participate, only 58 patients agreed to participate, of which 37 patients agreed to undergo the muscle biopsy procedure ([Fig. 3](#fig3){ref-type="fig"}). Therefore, the overall external validity of the study may be questioned. However, this study still provides novel insight into the effects of strength training during ADT, and also highlights the importance of expanding the current knowledge on the muscular side effects of long-term ADT.

In sum, in this study, we observed no intervention effects on mitochondrial proteins and indicators of muscle cellular stress. This was contrary to our expectations and contrary to studies in healthy elderly. Importantly, we report no change in the concentration of mitochondrial enzymes, meaning that the absolute levels most likely are increased. Furthermore, reduced levels of HSP70 were observed within the STG following the intervention, and we speculate that this may be an indicator of a stabilisation of the cellular environment. Future studies should compare exercise effects on the muscle cellular level between patients on and off ADT; in addition, future studies should also investigate the effects of different antiandrogen treatment options on the muscle cellular level.
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[^1]: [s.d.]{.smallcaps}, standard deviation; BMI, body mass index; ADT, androgen deprivation therapy; rad, radiotherapy.
